Table 1.
Clinical characteristics at start of 3-year study
| Total group | |
|---|---|
| Number (females) | 43 (25) |
| Genetic subtype | |
| Deletion / mUPD / ICD / translocation | 18 / 20 / 4 /1 |
| Age at start of childhood GH treatment (yrs) | 7.6 (5.2 to 10.1) |
| Age at inclusion (yrs) | |
| - Males | 19.5 (18.7 to 20.7) |
| - Females | 18.4 (16.9 to 20.8) |
| Adult height (SDS) | −1.0 (− 1.7 to − 0.3) |
| BMI (kg/m2) | 24.5 (21.9 to 27.7) |
| BMI for age (SDS) | 0.9 (0.0 to 1.8) |
| BMI for PWS (SDS) | −1.4 (−2.0 to −0.7) |
| Fat mass percentage (SDS)a | 2.2 (1.7 to 2.5) |
| Fat mass percentage (%) | 40.9 (34.4 to 45.6) |
| Lean body mass (SDS)a | −2.3 (− 2.8 to −1.4) |
| GH-dose (mg/m2/day) | 0.33 (0.33 to 0.59) |
| GH-dose (mg/kg/day) | 0.012 (0.012 to 0.021) |
| IGF-I SDSa | 1.5 (0.6 to 2.0) |
Data expressed as median (IQR)
mUPD Maternal uniparental disomy, ICD Imprinting center defect, GH Growth hormone
aFM% SDS, LBM SDS and IGF-I SDS were calculated according to age- and sex-matched Dutch references [25]